Cytokinetics Files 8-K: Financial Statements and Exhibits
Ticker: CYTK · Form: 8-K · Filed: May 13, 2024 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | May 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
Related Tickers: CYTK
TL;DR
Cytokinetics filed an 8-K with financial statements and exhibits on May 13, 2024.
AI Summary
On May 13, 2024, Cytokinetics, Incorporated filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates that Cytokinetics has submitted its financial statements and exhibits to the SEC, which is a standard procedural requirement for public companies.
Risk Assessment
Risk Level: low — The filing is a routine procedural submission of financial statements and exhibits, not indicating any new risks or material changes.
Key Players & Entities
- Cytokinetics, Incorporated (company) — Registrant
- May 13, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Cytokinetics, Incorporated.
On what date was this report filed?
The report was filed on May 13, 2024.
What is the state of incorporation for Cytokinetics, Incorporated?
Cytokinetics, Incorporated is incorporated in Delaware.
What is the principal executive office address of Cytokinetics, Incorporated?
The principal executive office address is 350 Oyster Point Boulevard, South San Francisco, California, 94080.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-05-13 16:09:19
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
Filing Documents
- cytk-20240513.htm (8-K) — 36KB
- cytk-ex99_1.htm (EX-99.1) — 60KB
- cytk-ex99_2.htm (EX-99.2) — 67KB
- img114956760_0.jpg (GRAPHIC) — 8KB
- img114956760_1.jpg (GRAPHIC) — 59KB
- img114956760_2.jpg (GRAPHIC) — 119KB
- img114956760_3.jpg (GRAPHIC) — 78KB
- img114956760_4.jpg (GRAPHIC) — 60KB
- img115880281_0.jpg (GRAPHIC) — 8KB
- 0000950170-24-058654.txt ( ) — 747KB
- cytk-20240513.xsd (EX-101.SCH) — 23KB
- cytk-20240513_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On May 13, 2024, Cytokinetics, Incorporated (the "Company") issued a press release announcing the release of the primary results form SEQUOIA-HCM that were presented in a late breaking clinical trial session at the European Society of Cardiology Heart Failure 2024 Congress and published in the New England Journal of Medicine. A selected copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In addition, also on May 13, 2024, the Company issued a second press release announcing the release of additional results from SEQUOIA-HCM at the late breaking clinical trial session at the European Society of Cardiology Heart Failure 2024 Congress. A selected copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated May 13, 2024 (Primary Results) 99.2 Press Release dated May 13, 2024 (Additional Results)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: May 13, 2024 By: /s/ John O. Faurescu John O. Faurescu, Esq. Associate General Counsel & Secretary